Generic Tagrisso (Osimertinib)

Osimertinib is the active ingredient in Tagrisso®, AstraZeneca's third-generation EGFR inhibitor for non-small cell lung cancer. Generic osimertinib contains the same active ingredient at the same strengths and is produced by licensed pharmaceutical manufacturers. For patients paying out of pocket, the generic can cost significantly less than the originator brand. Used as prescribed by a licensed medical professional.

Tagrisso® is the originator brand name for osimertinib, developed by AstraZeneca. It is a targeted oncology therapy prescribed in the management of EGFR-mutation-positive non-small cell lung cancer, including tumours carrying the T790M resistance mutation. As a prescription-only medicine, it is used under the supervision of a qualified oncologist who will confirm that your tumour carries a relevant EGFR mutation before treatment.

Osimertinib belongs to a class of medicines called tyrosine kinase inhibitors. In simple terms, it targets the EGFR protein signal that can drive the growth of certain lung-cancer cells. By selectively blocking this signal, the medicine is used as part of a treatment plan directed by your oncologist. It does not work for lung cancers that do not carry the relevant EGFR mutation, which is why testing is required first.

Osimertinib is prescribed for adults with non-small cell lung cancer whose tumours carry specific EGFR mutations, as confirmed by molecular testing. Your oncologist decides whether it is appropriate based on your diagnosis, mutation status, prior treatments, and overall health.

Osimertinib is commonly prescribed as one 80 mg tablet once daily, taken at about the same time each day, with or without food. If a tablet cannot be swallowed whole, the patient leaflet describes how it may be dispersed in water. Your oncologist may adjust the dose or pause treatment based on tolerability and any side effects.

Never change your dose on your own.

Reported side effects of osimertinib may include diarrhoea, rash or dry skin, changes to the nails, mouth sores, and tiredness. Less commonly, effects on the lungs, heart rhythm, or blood counts can occur, which is why your oncologist monitors you during treatment.

Report new or worsening symptoms to your doctor promptly. This is not a complete list — see the patient information leaflet.

Store as directed on the patient information leaflet, usually at room temperature away from moisture and out of reach of children. Always follow the storage guidance supplied with your medicine.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor. Earlier-generation medicines in the same family include erlotinib (the active ingredient in Tarceva) and gefitinib. The key practical difference is that osimertinib was designed to remain active against the T790M resistance mutation, which can develop after treatment with first-generation inhibitors. It is also designed to reach the central nervous system more effectively. Which medicine is appropriate depends entirely on your tumour's mutation profile and treatment history — a decision only your oncologist can make after molecular testing. This page is for cost and access information, not for choosing a therapy.

Branded Tagrisso carries the cost of the original research, clinical trials, and global marketing that brought osimertinib to market, protected for years by patents. In countries where patents have expired or where generics are produced under licence, licensed pharmaceutical manufacturers can make the identical active ingredient without those overheads, which is why generic osimertinib is typically priced far lower. The medicine itself — osimertinib mesylate — is the same molecule at the same strength. For patients paying out of pocket, or in regions where the brand is not reimbursed, this price gap is often the difference between continuing or interrupting treatment, which is why so many people search for affordable generic options.

Osimertinib is a long-term daily therapy that your oncology team monitors closely. Expect periodic scans to assess response, blood tests to watch blood counts and liver function, and occasional heart-rhythm (ECG) checks, since EGFR inhibitors can affect these. Many people take osimertinib for extended periods with manageable side effects, but you should report new breathlessness, cough, or fever promptly, as these can signal less common lung-related effects. Never stop or pause treatment on your own — continuity matters, and any change should be planned with your doctor.